Modeling myeloproliferative neoplasms: From mutations to mouse models and back again

Area of Science:

• Hematology
• Oncology
• Genetics

Background:

• Myeloproliferative neoplasms (MPNs) are classified by WHO, with genetic lesions impacting diagnosis and treatment.
• Understanding genotype-phenotype relationships is key to identifying driver mutations for MPN development and maintenance.
• Human studies identify potential driver mutations, but murine models are essential for confirming causality and pre-clinical testing.

Purpose of the Study:

• To review existing MPN mouse models.
• To assess the pathogenetic roles of gene mutations in MPNs using these models.
• To evaluate MPN-like phenotypes in genetically modified mice.

Main Methods:

• Review of literature on MPN mouse models.
• Analysis of studies linking genetic mutations to MPN development.
• Examination of genetically modified mice exhibiting MPN-like phenotypes.

Main Results:

• MPN mouse models are instrumental in validating driver mutations identified in human patients.
• These models facilitate pre-clinical testing of targeted therapeutic interventions for MPNs.
• Genetically modified mice can recapitulate MPN-like phenotypes, aiding in disease understanding.

Conclusions:

• Murine models are indispensable for demonstrating the causative role of genetic mutations in MPNs.
• MPN mouse models are critical for advancing the development of curative targeted therapies.
• The review highlights the utility of mouse models in MPN research and therapeutic development.